TrialsgrambetaRCTs are beautiful

IMPROVE-IT

2015

Improved Reduction of Outcomes: Vytorin Efficacy International Trial

In 18,144 patients post-ACS, ezetimibe added to simvastatin further reduced CV death, MI, UA, revasc or stroke compared with simvastatin alone.

Result

Efficacy: Composite CV eventsHR 0.94

Below 1 favours ezetimibe added to simvastatin, above 1 favours simvastatin alone.

Event rates
Absolute difference
2.0 points

The absolute difference is derived from the event rates.

Also reported: Mean LDL 54 vs 70 mg/dL.

Original publication
Subtopic
Non-statin LDL
Design
Double-blind RCT, median 6 yr
Relevance
Important: one of several pillars.
Source
Cannon CP, et al. N Engl J Med. 2015;372(25):2387-2397.doi 10.1056/NEJMoa1410489

Discussion & critique

First non-statin LDL trial to show outcome benefit: validated the 'lower-is-better' LDL hypothesis. Modest absolute risk reduction; cost-effectiveness debated.

Discussed in podcasts